Botswana’s ambitious fight against HIV is facing a significant challenge as new findings reveal that nearly one-third of people living with HIV (PLWH) on antiretroviral therapy (ART) with detectable viraemia in the national program have developed drug resistance mutations (DRMs).
The study which was conducted within the Botswana National ART Program highlights a concerning prevalence of resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) despite the latter being less commonly used in current ART regimens. While resistance to dolutegravir, a commonly used integrase inhibitor in Botswana, remains low, medical experts are calling for a review of treatment protocols.
There's more to this story
But to keep reading, we need you to subscribe.
Investigative journalism is an indispensable part of a healthy society, but it's also expensive to produce. We are reliant on subscriptions to fund our work, and while you can enjoy most of our stories for free, a small number of premium features are reserved for subscribers.
You can subscribe for one week, a month or a full year - the choice is yours.
Save 77% on an annual subscription. Click here to find out how.
Existing subscribers can log in to keep reading here.
